<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lutetium Lu-177 dotatate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lutetium Lu-177 dotatate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lutetium Lu-177 dotatate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="116618" href="/d/html/116618.html" rel="external">see "Lutetium Lu-177 dotatate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51083210"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lutathera</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53998158"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Lutathera</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F51010482"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F51084582"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premedications and concomitant medications are required.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd3fa608-a145-4d8b-bf97-1ef6968c1ac6">Gastroenteropancreatic neuroendocrine tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroenteropancreatic neuroendocrine tumors: IV:</b> 7.4 GBq (200 mCi) every 8 weeks (±1 week) for a total of 4 doses (Strosberg 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Premedication and concomitant medications:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Somatostatin analogs: </i>Discontinue long-acting somatostatin analogs (eg, long-acting octreotide) at least 4 weeks prior to initiating lutetium Lu 177 dotatate therapy. Administer short-acting octreotide in the interim as needed, but discontinue at least 24 hours prior to initiating lutetium Lu 177 dotatate therapy. During lutetium Lu 177 dotatate therapy, administer long-acting octreotide 30 mg IM between 4 to 24 hours after each lutetium Lu 177 dotatate dose. Do not administer long-acting octreotide within 4 weeks of each subsequent lutetium Lu 177 dotatate dose; short-acting octreotide may be given for symptomatic management, but discontinue at least 24 hours before each lutetium Lu 177 dotatate dose. Continue long-acting octreotide 30 mg IM every 4 weeks after completion of the full course of lutetium Lu 177 dotatate treatment until disease progression or for 18 months following treatment initiation as directed by the healthcare provider.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Antiemetic:</i> Administer antiemetics before the recommended amino acid solution.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Amino acid solution:</i> Initiate an IV infusion of a sterile amino acid solution 30 minutes before administering lutetium Lu 177 dotatate. The solution should contain L-lysine (between 18 to 25 g) and L-arginine (between 18 to 25 g) in a total volume of 1 to 2 L and have an osmolarity of &lt;1,050 mOsmol/L. Continue the infusion during and for at least 3 hours after completion of the lutetium Lu 177 dotatate dose; do not decrease the dose of the amino acid solution if the dose of lutetium Lu 177 dotatate is reduced. See "Administration".</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hypersensitivity reaction:</i> Premedicate if a prior grade 1 or 2 hypersensitivity reaction occurred with lutetium Lu 177 dotatate administration. Do not rechallenge if a grade 3 or 4 hypersensitivity reaction occurred with a prior infusion.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F51084585"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Calculate CrCl using the Cockcroft-Gault equation with actual body weight.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary. Monitor renal function more frequently; patients may be at a greater risk of toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal toxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;40 mL/minute, <b>or</b> 40% increase from baseline serum creatinine, <b>or</b> 40% decrease from baseline CrCl: Withhold lutetium Lu 177 dotatate dose until resolution or return to baseline; resume therapy at a reduced dose of 3.7 GBq (100 mCi) in patients with resolution or return to baseline. If the reduced dose does not result in renal toxicity, administer lutetium Lu 177 dotatate at 7.4 GBq (200 mCi) for the next dose. Permanently discontinue lutetium Lu 177 dotatate for renal toxicity requiring a treatment delay of ≥16 weeks, or for recurrent renal toxicity.</p></div>
<div class="block doha drugH1Div" id="F51084587"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (bilirubin &gt;3 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Bilirubin &gt;3 times ULN (grade 3 or 4) <b>or </b>albumin &lt;30 g/L with INR &gt;1.5: Withhold lutetium Lu 177 dotatate dose until resolution or return to baseline; resume therapy at a reduced dose of 3.7 GBq (100 mCi) in patients with resolution or return to baseline. If the reduced dose does not result in hepatotoxicity, administer lutetium Lu 177 dotatate at 7.4 GBq (200 mCi) for the next dose. Permanently discontinue lutetium Lu 177 dotatate for hepatotoxicity requiring a treatment delay of ≥16 weeks, or for recurrent hepatotoxicity.</p></div>
<div class="block dot drugH1Div" id="F51084596"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-4em;margin-left:4em;">
<b>Hematologic toxicity</b></p>
<p style="text-indent:-4em;margin-left:6em;">
<i>Anemia or neutropenia (grade 3 or 4)</i>: Withhold lutetium Lu 177 dotatate dose until ≤ grade 2; resume therapy at a reduced dose of 3.7 GBq (100 mCi) in patients with complete or partial resolution. If the reduced dose does not result in ≥ grade 3 anemia or neutropenia, administer lutetium Lu 177 dotatate at 7.4 GBq (200 mCi) for the next dose. Permanently discontinue lutetium Lu 177 dotatate for ≥ grade 3 anemia or neutropenia requiring a treatment delay of ≥16 weeks, or for recurrent grade 3 or 4 anemia or neutropenia.</p>
<p style="text-indent:-4em;margin-left:6em;">
<i>Thrombocytopenia (grade 2, 3, or 4)</i>: Withhold lutetium Lu 177 dotatate dose until ≤ grade 1; resume therapy at a reduced dose of 3.7 GBq (100 mCi) in patients with complete or partial resolution. If the reduced dose does not result in ≥ grade 2 thrombocytopenia, administer lutetium Lu 177 dotatate at 7.4 GBq (200 mCi) for the next dose. Permanently discontinue lutetium Lu 177 dotatate for ≥ grade 2 thrombocytopenia requiring a treatment delay of ≥16 weeks, or for recurrent grade 2, 3, or 4 thrombocytopenia.</p>
<p style="text-indent:-4em;margin-left:6em;">
<i>Note</i>: Dose modifications are not required for hematological toxicities grade 3 or 4 due to lymphopenia.</p>
<p style="text-indent:-4em;margin-left:4em;">
<b>Hypersensitivity reactions (including allergic reaction and anaphylaxis):</b> Discontinue lutetium Lu 177 dotatate infusion when signs/symptoms consistent with a severe hypersensitivity reaction occur and initiate appropriate management. Permanently discontinue lutetium Lu 177 dotatate for grade 3 or 4 hypersensitivity reactions.</p>
<p style="text-indent:-4em;margin-left:4em;">
<b>Nonhematologic toxicity:</b></p>
<p style="text-indent:-4em;margin-left:6em;">
<i>Grade 3 or 4 toxicity</i>: Withhold lutetium Lu 177 dotatate dose until ≤ grade 2; resume therapy at a reduced dose of 3.7 GBq (100 mCi) in patients with complete or partial resolution. If the reduced dose does not result in ≥ grade 3 toxicity, administer lutetium Lu 177 dotatate at 7.4 GBq (200 mCi) for the next dose. Permanently discontinue lutetium Lu 177 dotatate for ≥ grade 3 adverse reaction requiring a treatment delay of ≥16 weeks, or for recurrent grade 3 or 4 toxicity.</p></div>
<div class="block doe drugH1Div" id="F51084583"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F51089966"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse drug reactions are reported for adults from combination therapy trials with octreotide.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (14%), hypertension (12%), peripheral edema (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (82%), hyperkalemia (19%), hypernatremia (17%), hyperuricemia (34%), hypocalcemia (32%), hypoglycemia (15%), hypokalemia (26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (26%), decreased appetite (21%), diarrhea (26%), nausea (65%), vomiting (53%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (81%), leukopenia (55%; grades 3/4: 2%), lymphocytopenia (90%; grades 3/4: 44%), neutropenia (26%; grades 3/4: 3%), thrombocytopenia (53%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (66%), increased serum alanine aminotransferase (43%), increased serum alkaline phosphatase (65%), increased serum aspartate aminotransferase (50%), increased serum bilirubin (30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (12%), dizziness (17%), fatigue (38%), headache (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (13%), limb pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (85%), renal failure syndrome (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (10%), dysgeusia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urotoxicity (8%, radiation-related)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Myelodysplastic syndrome (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (5%), neck pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Angioedema, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F51010485"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to lutetium Lu 177 dotatate or any component of the formulation; severe renal impairment (CrCl &lt;30 mL/minute); pregnancy.</p></div>
<div class="block war drugH1Div" id="F51084572"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Myelosuppression (anemia, thrombocytopenia, and neutropenia [all grades]) occurred more frequently in patients receiving lutetium Lu 177 dotatate versus long-acting octreotide. In a clinical study, the platelet nadir occurred at a median of 5.1 months following the first lutetium Lu 177 dotatate dose. Over two-thirds of patients who developed thrombocytopenia recovered to baseline or normal platelet levels with a median platelet recovery time of 2 months.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatic effects have occurred with lutetium Lu 177 dotatate administration; hepatic tumor hemorrhage, edema, or necrosis, and intrahepatic congestion and cholestasis have been reported very rarely. Patients with hepatic metastasis may have an increased risk of hepatotoxicity due to radiation exposure from lutetium Lu 177 dotatate infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuroendocrine hormonal crisis: Neuroendocrine hormonal crises (eg, flushing, diarrhea, bronchospasm, hypotension) have occurred (rarely) following the lutetium Lu 177 dotatate dose. Reactions typically occurred during or within 24 hours after the initial dose. Hypercalcemia was reported in a small number of patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Renal failure has occurred following lutetium Lu 177 dotatate administration; the time to renal failure ranged from 3 to 36 months following infusion in one clinical trial. Some patients had underlying renal impairment or other risk factors for renal failure such as diabetes or hypertension. Administer concomitantly with a recommended amino acid solution before, during, and after lutetium Lu 177 dotatate infusion to decrease proximal tubule reabsorption (and decrease radiation exposure to the kidneys); do not decrease the dose of the amino acid solution if lutetium Lu 177 dotatate is dose reduced. Patients should hydrate and urinate frequently during and after lutetium Lu 177 dotatate infusion. Patients with baseline mild or moderate renal impairment may be at increased risk for renal toxicity following lutetium Lu 177 dotatate administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancies: In clinical trials, myelodysplastic syndrome (MDS) and leukemia have been reported in a small percentage of patients who received lutetium Lu 177 dotatate. In one study, the median time to development was 29 months (range: 9 to 45 months) and 55 months (range: 32 to 125 months) for MDS and leukemia, respectively. Long-term cumulative radiation exposure is associated with an increased risk for cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special handling:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients, health care personnel, and household contacts. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. Radiation may be detected in the urine for up to 30 days following lutetium Lu 177 dotatate infusion; administration of this agent contributes to the patient's long-term cumulative radiation exposure which is associated with an increased cancer risk.</p></div>
<div class="block foc drugH1Div" id="F51083211"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lutathera: 370 MBq/mL (10 mCi/mL) (1 ea)</p></div>
<div class="block geq drugH1Div" id="F51083209"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51131768"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lutathera Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">370 mbq/ml (per each): $67,075.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53998159"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lutathera: 370 MBq/mL (10 mCi/mL) (1 ea)</p></div>
<div class="block adm drugH1Div" id="F51084598"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as an IV infusion; do not administer as an IV bolus. Administer via the gravity, peristaltic pump, or syringe pump method when administering recommended dosage; for reduced dosages following an adverse reaction, administer by peristaltic or syringe pump method; when using the gravity method for a reduced dose, adjust the dose before administration to avoid delivery of an incorrect volume. Refer to product labeling for further details. Monitor for signs/symptoms of hypersensitivity during infusion and for at least 2 hours after infusion. Premedicate before infusion for patients who have had prior grade 1 or 2 hypersensitivity reactions with lutetium Lu 177 dotatate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Gravity method:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Insert a 2.5 cm, 20-gauge needle (short needle) into the lutetium Lu 177 dotatate vial and connect via a catheter to a 500 mL sterile NS solution. Do not allow the short needle to touch the lutetium Lu 177 dotatate solution in the vial and do not connect this short needle to the patient. Do not allow NS to flow into the lutetium Lu 177 dotatate vial prior to infusion initiation and do not inject lutetium Lu 177 dotatate directly into the NS solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Insert a separate 9 cm, 18-gauge (long needle) into the lutetium Lu 177 dotatate vial; ensure that this long needle touches and is secured to the bottom of the lutetium Lu 177 dotatate vial during the entire infusion. Connect the long needle to the patient by an IV catheter that is prefilled with sterile NS solution and that is used only for the lutetium Lu 177 dotatate infusion into the patient.</p>
<p style="text-indent:-2em;margin-left:6em;">Use a clamp or an infusion pump to regulate the flow of the NS solution via the short needle into the lutetium Lu 177 dotatate vial at a rate of 50 to 100 mL/hour for 5 to 10 minutes, and then 200 to 300 mL/hour for an additional 25 to 30 minutes. The NS solution (entering the vial through the short needle) will carry the lutetium Lu 177 dotatate solution from the vial to the patient through the IV catheter connected to the long needle (over a total duration of 30 to 40 minutes).</p>
<p style="text-indent:-2em;margin-left:6em;">During the infusion, ensure that the level of solution in the lutetium Lu 177 dotatate vial remains constant. Once the level of radioactivity is stable for at least 5 minutes, disconnect the vial from the long needle line and clamp the NS line. Once the infusion is complete, flush the line with 25 mL NS.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peristaltic pump method:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Insert a filtered 2.5 cm, 20-gauge needle (short venting needle) into the lutetium Lu 177 dotatate vial. Do not allow the short needle to touch the lutetium Lu 177 dotatate solution in the vial and do not connect this short needle directly to the patient or the peristaltic pump.</p>
<p style="text-indent:-2em;margin-left:6em;">Insert a separate 9 cm, 18-gauge (long needle) into the lutetium Lu 177 dotatate vial; ensure that this long needle touches and is secured to the bottom of the lutetium Lu 177 dotatate vial during the entire infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">Connect the long needle and sterile NS solution to a 3-way stopcock valve via appropriate tubing. Connect the output of the 3-way stopcock valve to tubing installed on the input side of the peristaltic infusion pump according to manufacturer's instruction.</p>
<p style="text-indent:-2em;margin-left:6em;">Prime the line by opening the 3-way stopcock valve and pumping the lutetium Lu 177 dotatate infusion through the tubing until it reaches the exit of the valve. Prime the IV catheter that will be connected to the patient by opening the 3-way stopcock valve to the sterile NS solution and pumping the sterile NS solution until it exits the end of the catheter tubing.</p>
<p style="text-indent:-2em;margin-left:6em;">Connect the primed IV catheter to the patient and set the 3-way stopcock valve so that the lutetium Lu 177 dotatate infusion is in line with the peristaltic pump. Infuse an appropriate volume of lutetium Lu 177 dotatate over 30 to 40 minutes to administer the desired radioactivity. When the correct volume of lutetium Lu 177 dotatate infusion has been delivered, stop the peristaltic pump and then change the position of the 3-way stopcock valve so that the peristaltic pump is in line with the sterile NS solution. Restart the peristaltic pump and infuse an IV flush of 25 mL NS solution through the IV catheter to the patient.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Syringe pump method:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Use a disposable syringe fitted with a syringe shield and a disposable sterile 9 cm, 18-gauge (long needle) to withdraw the appropriate volume of lutetium Lu 177 dotatate to deliver the desired radioactivity; a filtered 2.5 cm, 20-gauge (short venting needle) may be used to aid in the withdrawal and reduce the resistance of the pressurized vial; ensure the short needle does not touch the lutetium Lu 177 dotatate solution in the vial.</p>
<p style="text-indent:-2em;margin-left:6em;">Connect the syringe into the shielded pump and include a 3-way stopcock valve between the syringe and IV catheter prefilled with NS for lutetium Lu 177 dotatate for administration to the patient. Infuse an appropriate volume of lutetium Lu 177 dotatate over 30 to 40 minutes to administer the desired radioactivity.</p>
<p style="text-indent:-2em;margin-left:6em;">When the correct volume of lutetium Lu 177 dotatate infusion has been delivered, stop the syringe pump and then change the position of the 3-way stopcock valve to flush the syringe with 25 mL of NS solution. Restart the syringe pump. After the flush of the syringe has completed, infuse an IV flush of 25 mL NS solution through the IV catheter to the patient.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Antiemetics:</i> Administer antiemetics prior to amino acid solution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Amino acid solution:</i> Use a 3-way valve to administer the amino acid solution using the same venous access as the lutetium Lu 177 dotatate infusion, or administer the amino acid solution through a separate venous access in the patient's other arm. Continue the amino acid infusion during and for at least 3 hours after completion of the lutetium Lu 177 dotatate infusion.</p></div>
<div class="block use drugH1Div" id="F51010484"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Gastroenteropancreatic neuroendocrine tumors:</b> Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults, including foregut, midgut, and hindgut neuroendocrine tumors.</p></div>
<div class="block mst drugH1Div" id="F51084561"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lutathera may be confused with Lutera</p>
<p style="text-indent:-2em;margin-left:4em;">Lutetium Lu 177 dotatate may be confused with Lutetium Lu 177 vipivotide tetraxetan.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and health care personnel. Use under supervision of experienced personnel. Use waterproof gloves and effective radiation shielding when handling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F51083834"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F51083831"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Lutetium Lu 177 Dotatate. Management: Avoid repeated use of high-doses of corticosteroids during treatment with lutetium Lu 177 dotatate. Use of corticosteroids is still permitted for the treatment of neuroendocrine hormonal crisis. The effects of lower corticosteroid doses is unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: May diminish the therapeutic effect of Lutetium Lu 177 Dotatate. Specifically, the therapeutic effect of Lutetium Lu 177 Dotatate may be diminished if the timing of Somatostatin Analog administration is not carried out as recommended. Management: Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to lutetium Lu 177 dotatate dose. Administer short and long-acting octreotide during treatment as recommended. See full interaction monograph<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F51084565"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to initiating therapy. Patients who could become pregnant should use effective contraception during therapy and for 7 months after the last dose. Patients with partners who could become pregnant should use effective contraception during therapy and for 4 months after the last dose.</p>
<p style="text-indent:0em;margin-top:2em;">Radiation associated with lutetium Lu 177 dotatate therapy may cause infertility in males and females, which may be temporary or permanent.</p></div>
<div class="block pri drugH1Div" id="F51084564"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, lutetium Lu 177 dotatate may cause fetal harm if exposure occurs during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F51084566"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if lutetium Lu 177 dotatate is present in breast milk. Due to the potential for serious adverse events in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy or for 2.5 months after the last dose.</p></div>
<div class="block mop drugH1Div" id="F51084600"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor blood cell counts; serum creatinine and creatinine clearance (monitor more frequently in patients with baseline renal impairment); transaminases, bilirubin, and albumin. Verify pregnancy status prior to initiating therapy in patients who could become pregnant. Monitor for signs/symptoms of neuroendocrine hormonal crisis (eg, flushing, diarrhea, bronchospasm, hypotension) and secondary malignancies (myelodysplastic syndrome and leukemia). Monitor closely for signs/symptoms of hypersensitivity reactions (including angioedema and anaphylaxis) during and for a minimum of 2 hours following lutetium Lu 177 dotatate administration; administer in a setting where cardiopulmonary resuscitation medication and equipment are available.</p></div>
<div class="block pha drugH1Div" id="F51084576"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Lutetium Lu 177 dotatate is a beta- and gamma-emitting radionuclide which binds to somatostatin receptors (Strosberg 2017). It binds with highest affinity to subtype 2 receptors (SSRT2); after binding to somatostatin-expressing cells, the lutetium Lu 177 dotatate compound is internalized. Beta emission induces cellular damage by forming free radicals in somatostatin receptor-positive and surrounding cells.</p></div>
<div class="block phk drugH1Div" id="F51084577"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 460 L; lutetium Lu 177 dotatate distributes into kidneys, tumor lesions, liver, spleen, and (in some patients) pituitary gland and thyroid within 4 hours after administration. The maximum penetration into tissue is 2.2 mm (mean penetration: 0.67 mm).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Non-radioactive form of lutetium dotatate: 43% to plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean terminal blood half-life: 71 ± 28 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily renal; prolonged elimination in the urine is expected; however, &gt;99% of lutetium Lu 177 dotatate will be eliminated within 14 days after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 4.5 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F51114776"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lutathera</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Lutathera (lutetium Lu 177 dotatate) [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lutathera.2">
<a name="Lutathera.2"></a>Lutathera (lutetium Lu 177 oxodotreotide) [product monograph]. Millburn, NJ: Advanced Accelerator Applications USA; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28076709">
<a name="28076709"></a>Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. <i>N Engl J Med.</i> 2017;376(2):125-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lutetium-lu-177-dotatate-drug-information/abstract-text/28076709/pubmed" id="28076709" target="_blank">28076709</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  U.S. Nuclear Regulatory Commission (USNRC). Regulatory Guide 8.39. Release of patients administered radioactive materials. 1997.</div>
</li></ol></div><div id="topicVersionRevision">Topic 116519 Version 83.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
